UMB Bank n.a. Sells 1,157 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

UMB Bank n.a. decreased its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 2.9% during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 39,037 shares of the medical research company's stock after selling 1,157 shares during the quarter. UMB Bank n.a.'s holdings in Thermo Fisher Scientific were worth $19,425,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Perennial Advisors LLC increased its stake in Thermo Fisher Scientific by 1.3% in the 1st quarter. Perennial Advisors LLC now owns 15,737 shares of the medical research company's stock valued at $7,831,000 after buying an additional 197 shares during the last quarter. Sivia Capital Partners LLC increased its stake in Thermo Fisher Scientific by 21.6% in the 1st quarter. Sivia Capital Partners LLC now owns 891 shares of the medical research company's stock valued at $443,000 after buying an additional 158 shares during the last quarter. Perkins Coie Trust Co increased its stake in Thermo Fisher Scientific by 240.0% in the 1st quarter. Perkins Coie Trust Co now owns 425 shares of the medical research company's stock valued at $211,000 after buying an additional 300 shares during the last quarter. WealthBridge Investment Counsel Inc. increased its stake in Thermo Fisher Scientific by 2.4% in the 1st quarter. WealthBridge Investment Counsel Inc. now owns 11,487 shares of the medical research company's stock valued at $5,716,000 after buying an additional 265 shares during the last quarter. Finally, Intergy Private Wealth LLC increased its stake in Thermo Fisher Scientific by 5.8% in the 1st quarter. Intergy Private Wealth LLC now owns 419 shares of the medical research company's stock valued at $208,000 after buying an additional 23 shares during the last quarter. Hedge funds and other institutional investors own 89.23% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on TMO shares. UBS Group decreased their price target on shares of Thermo Fisher Scientific from $715.00 to $500.00 and set a "buy" rating for the company in a research note on Thursday, April 24th. Stifel Nicolaus decreased their price target on shares of Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating for the company in a research note on Thursday, April 24th. Wall Street Zen upgraded shares of Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research note on Wednesday, May 21st. Argus decreased their price target on shares of Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating for the company in a research note on Tuesday, April 29th. Finally, Evercore ISI decreased their price target on shares of Thermo Fisher Scientific from $585.00 to $500.00 and set an "outperform" rating for the company in a research note on Thursday, April 24th. Four analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. Based on data from MarketBeat.com, Thermo Fisher Scientific currently has an average rating of "Moderate Buy" and a consensus price target of $605.30.

Thermo Fisher Scientific Price Performance

Shares of TMO traded up $3.63 during mid-day trading on Friday, reaching $401.99. 2,629,538 shares of the stock traded hands, compared to its average volume of 1,910,947. The firm has a fifty day moving average price of $420.74 and a 200 day moving average price of $495.81. The company has a market cap of $151.75 billion, a price-to-earnings ratio of 24.32, a price-to-earnings-growth ratio of 2.99 and a beta of 0.78. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59. Thermo Fisher Scientific Inc. has a 1 year low of $390.50 and a 1 year high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.10 by $0.05. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. The company had revenue of $10.36 billion during the quarter, compared to the consensus estimate of $10.23 billion. During the same period in the previous year, the firm posted $5.11 EPS. The firm's revenue was up .2% compared to the same quarter last year. As a group, equities research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 15th. Stockholders of record on Friday, June 13th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.43%. The ex-dividend date of this dividend is Friday, June 13th. Thermo Fisher Scientific's dividend payout ratio is currently 10.09%.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the business's stock in a transaction on Monday, April 28th. The shares were sold at an average price of $429.93, for a total value of $128,979.00. Following the completion of the sale, the executive vice president now directly owns 23,167 shares of the company's stock, valued at $9,960,188.31. The trade was a 1.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Michael A. Boxer sold 3,775 shares of the business's stock in a transaction on Monday, March 10th. The stock was sold at an average price of $532.52, for a total transaction of $2,010,263.00. Following the completion of the sale, the senior vice president now directly owns 10,816 shares of the company's stock, valued at $5,759,736.32. This represents a 25.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.33% of the stock is currently owned by insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.